Exact Sciences (NASDAQ: EXAS) 30% LOWER; said related to USPSTF update on colorectal cancer screening.Illumina (NASDAQ: ILMN) 14.4% LOWER; announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Whitney Tilson Says Exact Sciences (EXAS) Still a Great ShortOctober 7, 2015 10:20 AM Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines October 7, 2015 6:50 AM Lake Street Capital Markets Downgrades Exact Sciences (EXAS) to HoldOctober 6, 2015 1:44 PM B. Riley Reiterates Buy on Lionsgate (LGF) Following Reports of Advanced Talks to Complete a Starz (STRZA) Merger October 6, 2015 9:12 AM Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines October 6, 2015 8:45 AM Canaccord Genuity Reiterates Buy on Illumina (ILMN) Following 3Q15 Preliminary Results October 6, 2015 8:37 AM Benchmark Downgrades Exact Sciences (EXAS) to HoldOctober 6, 2015 8:03 AM Piper Jaffray Cuts Price target on Illumina (ILMN) Following Preliminary 3Q15 Results October 6, 2015 8:01 AM Impact on Exact Sciences (EXAS) from USPSTF Guidlines 'Unclear', Jefferies Says; Would Be Buyers on WeaknessOctober 6, 2015 6:53 AM Exact Sciences (EXAS) Issues Statement on USPSTF Colorectal Cancer Screening Draft RecommendationOctober 6, 2015 6:29 AM Exact Sciences (EXAS) Pleased Cologuard Included in USPSTF Draft Colorectal Cancer Screening GuidelinesOctober 6, 2015 6:28 AM